Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure
Status:
Completed
Trial end date:
2021-04-23
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the efficacy and safety of continuous intravenous
administration of low dose iloprost versus placebo for 72-hours, in 80 patients with COVID-19
suffering from respiratory failure. The study hypothesis is that iloprost may be beneficial
as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and
restore vascular integrity in COVID-19 patients suffering from respiratory failure caused by
endothelial breakdown, ultimately improving survival. Given that the pulmonary system, apart
from the brain, is the most highly vascularized vital organ in the body, extensive
endothelial damage is a central feature of acute respiratory distress syndrome (ARDS) with
respiratory failure being the rationale for the current study COMBAT-COVID-19.